Despite widespread recognition of hypertension, acute lowering of blood pressure is indicated in certain clinical situations constituting hypertensive emergencies and urgencies. In this brief discussion, certain new aspects in the management of hypertensive crises will be discussed.
In general, hypertensive crises can be divided into three classes. Hypertensive emergencies pose a significant and immediate threat to the patient's life, cardiovascular, neurologic and/or renal systems. Immediate blood pressure reduction in "hours" is necessary in hypertensive emergencies. Hypertensive urgencies are situations where the patient's elevated blood pressure ultimately poses a serious risk to the patient ifit is not treated aggressively. Examples of hypertensive urgencies are shown in Table 1 . In the last category, the blood pressure requires gradual reduction primarily to prevent longterm sequelae of untreated hypertension.
True hypertensive emergencies such as hypertension with acute heart failure and pulmonary edema or hypertensive encephalopathy still require initial blood pressure control with appropriate therapy and intensive care monitoring with intra-arterial blood pressure monitoring. Therapeutic choices available for the treatment of hypertensive crises are shown in Table 2 . This discussion will be limited to the use of new therapeutic agents.
Labetalol is a drug that possesses both alpha-blocking and beta-blocking properties and effectively lowers the blood pressure when given parenterally or by oral route.13 The parenteral form can be given either as a bolus or as a continuous infusion. In patients with low output heart failure, labetalol decreases peripheral vascular resistance without depressing the cardiac output. Continuous 20 mg/hour and doubled every hour up to 160 mg/hour until the desired lowering of the blood pressure is achieved. Bolus doses intravenously can be given as 1 mg/kg labetalol over three minutes or as a mini bolus of 20 mg over two minutes followed by incremental doses of 20 to 80 mg every ten minutes until the desired blood pressure is achieved. A blood pressure response should be evident in 5 to 30 minutes with a maximum effect at six hours. Labetalol has been shown to be efficacious in the setting ofperioperative hypertension and severe hypertension associated with myocardial infarction with no serious side effects. Due to its betablocking actions, labetalol should not be given to patients who have contraindications to the use of conventional beta-blockers. In contrast to the standard beta-blockers, however, labetalol is less likely to provoke bronchospasm and vasospasm.
Although not yet approved for the treatment of hypertension, nifedipine, a dihydropyridine calcium antagonist, is widely used for the emergency treatment of hypertension.46 Ten to 20 mg of nifedipine given sublingually or orally has been shown to lower the blood pressure within 10 to 15 minutes. The maximal Nifedipine has the additional advantages that its use does not require invasive hemodynamic monitoring. Care must be taken when discharging a patient from the emergency room after having lowered the blood pressure with nifedipine as the blood pressure may rise to his original level when the effect of the nifedipine wears out. Patients who are discharged following acute treatment should be provided close follow-up. Nifedipine is not associated with serious side effects. In some patients, reflex tachycardia may warrant coadministration of a beta-blocker. Minor side effects of nifedipine include localized edema, headache, flushing, and palpitations. Because nifedipine has been shown to increase cerebral blood flow in some patients, there is a theoretic possibility of worsening cerebral function in patients with hypertensive encephalopathy. The benefit: risk analysis ofthe utility ofnifedipine in specific hypertensive crises such as hypertensive encephelopathy remains to be determined by additional experience.
There are currently two angiotensin converting (ACE) inhibitors-captopril and enalapril-available for clinical use in the United States. These ACE inhibitors have proven to be effective in the treatment of patients with severe hypertension with or without acute hypertensive emergencies or urgencies. Their main mechanism of action appears to be the blockade ofthe renin-angiotensin system. The ACE inhibition is particularly useful in patients with a high renin level, although some patients with normal or low plasma renin activity may also respond. The possible differential effects of captopril and enalapril due to their structural dissimilarities will not be discussed in the context of this review.
A dose of25 mg of captopril, given orally, effectively blocks the renin-angiotensin system and a resultant fall in blood pressure is observed within 15 to 30 minutes.
The dose response curve for captopril is flat, and increasing the dose would not help in those patients whose blood pressure has not normalized with the initial dose. These patients would benefit by the addition ofa diuretic to potentiate the effect ofthe ACE inhibitor. The 
